Breaking News, Collaborations & Alliances

Codexis, Takeda Sign Gene Therapy Collaboration

Partnership to leverage Codexis’ protein engineering platform to advance novel gene therapies for rare genetic disorders

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Codexis, a protein engineering company and developer of novel biotherapeutics, has signed a strategic collaboration and license agreement with Takeda for the research and development of novel gene therapies for certain disease indications, including the treatment of lysosomal storage disorders and blood factor deficiencies.   Codexis will generate novel gene sequences encoding protein variants tailored to enhance efficacy as a result of increased activity, stability, and cellular uptake using it...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters